Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

Bristol-Myers Squibb Company ended Tuesday, December 23, 2025, slightly lower in regular trading, then steadied after the closing bell as investors digested a fresh legal headline tied to U.S. drug pricing—plus a growing list of end‑of‑year catalysts that could shape sentiment into 2026.

Bristol-Myers Squibb Company is back in the spotlight on Tuesday, December 16, 2025, as investors weigh a fresh Bank of America upgrade, a renewed value debate around the stock’s multiple, and a growing list of 2026 pipeline catalysts that could shape the post–patent-cliff narrative.

Dec. 12, 2025 — Bristol-Myers Squibb Company is back in the spotlight heading into year-end as investors weigh a fresh dividend increase, meaningful regulatory milestones in oncology, and a pipeline that has delivered both high-profile wins and frustrating setbacks in 2025. By mid-day Friday, BMY stock traded around $52.50, up roughly 2.5% , reflecting a market that's starting to re-price near-term catalysts even as longer-term questions—patent cliffs, trial readouts, and litigation—remain front and center.

Bristol Myers Squibb has packed a lot into the first week of December 2025 – from a surprise update on a key Alzheimer’s drug trial to major hematology data at ASH 2025 and a legal setback over its Celgene acquisition. All of this is landing on a stock that has finally bounced after years of underperformance but still trades as a high‑yield value name.